| |
ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. 
|
|
Today’s Big NewsDec 5, 2023 |
|
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility. 
|
|
| By Angus Liu Eli Lilly has pushed back the deadline of its tender offer for radiotherapy company Point Biopharma’s shares for a second time. According to two senior executives, Lilly’s current predicament is caused not by any internal factors but by Point’s rival, Novartis. |
|
|
|
By Nick Paul Taylor Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K inhibitor has yielded a improved progression-free survival (PFS) in phase 3, teeing up talks with regulatory authorities. |
By Gabrielle Masson Days away from an FDA decision on a sickle cell gene therapy, CRISPR Therapeutics is ditching its “first-generation” allogeneic CAR-T candidates and expanding into autoimmune disease. |
Sponsored by Cell Signaling Technology CST fellow Amrik Singh outlines some of the key progress being made around CAR-T therapy and the impact that this highly specialized technique can have on cancer patients, even those who have been previously unresponsive to other forms of treatment. |
|
With XenoTech part of BioIVT, you now have access to a truly best-in-class portfolio that includes human and animal hepatocytes, microsomes, S9 and more. View characteristics, pricing, and… Create a Quote >> 
|
|
By Gabrielle Masson The Flagship-founded Axcella Health is closing its doors, with stockholders approving the dissolution of the metabolic modulator biotech yesterday. |
Sponsored by IQVIA IQVIA’s new technologies are changing clinical trials, reducing the administrative burden on staff and improving insights for sponsors. |
By Annalee Armstrong Replimune’s RP1 is an “active agent” according to CEO Philip Astley-Sparke, but it didn’t achieve the primary endpoints of complete response or overall response in a phase 2 trial of patients with a type of skin cancer. |
By Max Bayer RNA biotech ReNAgade Therapeutics is laying off roughly 10% of its team after launching six months ago with $300 million. The company said at the time that the immediate focus would be prioritizing an early list of programs. |
By Annalee Armstrong After heralding data last month showing that the multiple sclerosis candidate fenebrutinib may have crossed the blood-brain barrier, Genentech revealed quietly last week that the program has been placed on a partial clinical hold by the FDA in the U.S. |
By Annalee Armstrong Shares of Merus fell 6% Monday morning as an interim update for a bispecific therapy revealed three deaths in the lung cancer portion of an ongoing trial. |
By Nick Paul Taylor Another day, another artificial intelligence (AI) deal. Tuesday was Sanofi’s turn to partner up, striking a deal worth up to $140 million to work on the discovery of small molecules with its compatriot Aqemia. |
By Gabrielle Masson Odyssey Therapeutics has raised an $101 million series C to help get its next-gen precision immunomodulators and oncology medicines into the clinic. |
By Annalee Armstrong Another of Alto Neurosciences’ machine learning-derived, biomarker-based depression therapies has improved symptoms, boosting the case for the biotech’s precision psychiatry approach. |
By Helen Floersh BrainChild Bio, a newly-launched spinout of Seattle Children’s Hospital, is focused on childhood central nervous system cancers. Rather than starting with regulatory approval for its drugs in adults, the company will aim for a greenlight for peds patients first. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Andrea Park For the first time, according to researchers, an implanted device has successfully demonstrated long-term improvements following a traumatic brain injury. |
By Fraiser Kansteiner During an enterprise business review Tuesday, J&J laid out a range of expectations across the 2025 to 2030 timeframe. Chief among those, J&J says it will boast more than 10 drugs with peak sales potential of at least $5 billion, plus another 15-plus products with sales potential of at least $1 billion. |
By Nick Paul Taylor Chiesi is working with the BBC to show off its climate-conscious credentials, partnering with the British broadcaster on a web series episode about redesigning inhalers to reduce their environmental impact. |
By Heather Landi After spending nearly $20 billion to pick up Signify Health and Oak Street Health this year, CVS rebranded its health services business to "CVS Healthspire" as it plots its long-term growth strategy. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
Whitepaper Discover how cloud-based HPC and AI can transform drug discovery and accelerate time-to-market. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| Edison Ballroom, New York City |
|
|
| |
|
